<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02841215</url>
  </required_header>
  <id_info>
    <org_study_id>P140939</org_study_id>
    <nct_id>NCT02841215</nct_id>
  </id_info>
  <brief_title>Efficacy Study Between Two Different Dosages of an Antiparasitic in Patients With Crusted Scabies</brief_title>
  <acronym>GALECRUSTED</acronym>
  <official_title>A Randomized Controlled Double-blind Trial Assessing the Efficacy of a 400µg/kg Ivermectin /5% Permethrin / Emollient Cream Regimen in Patients With Crusted Scabies as Compared to a 200µg/kg Ivermectin /5% Permethrin /Emollient Cream Regimen</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Severe forms of scabies (crusted scabies and profuse scabies) require a specific treatment.&#xD;
      Ivermectin is a recommended treatment in common forms of scabies and represents a promising&#xD;
      treatment in crusted scabies in case reports. However, response to ivermectin remains&#xD;
      variable among studies, and there is no consensus on the schemes to adopt (dosages and&#xD;
      administrations). Ivermectin at 400 µg/kg has already been used, without showing toxicity (in&#xD;
      head lice treatment in particular). Investigators propose to demonstrate that 400µg/kg&#xD;
      ivermectin dosage will show better efficacy than a 200µg/kg in patients with severe forms of&#xD;
      scabies (crusted and profuse).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 11, 2017</start_date>
  <completion_date type="Anticipated">May 10, 2021</completion_date>
  <primary_completion_date type="Anticipated">April 10, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of a successful treatment defined by : -Two negative parasitologic and/or two dermoscopic exams</measure>
    <time_frame>Days 21+/-2 days</time_frame>
    <description>Parasitologic and/or dermoscopic exams will be perform at days 18 +/-2days and at days 21+/-2 days</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Rate of a successful treatment defined by : - A clinical response : disappearance of clinical active lesions</measure>
    <time_frame>Days 28+/- 2 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of adverse effects</measure>
    <time_frame>Days 18 +/-2 days, Days 21+/-2 days and Days 28+/-2 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Gale</condition>
  <condition>Severe Forms of Scabies</condition>
  <condition>Oral Parasitic Drug</condition>
  <condition>Ivermectin</condition>
  <arm_group>
    <arm_group_label>Oral ivermectin 400 µg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oral ivermectin 400 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Oral ivermectin 200 µg/kg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oral ivermectin 200 µg/kg + topical treatment (permethrin 5% cream) + emollient cream (Dexeryl® or other)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin 200 µg/kg</intervention_name>
    <description>Oral ivermectin 200 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other) daily on skin (D0 to D28)</description>
    <arm_group_label>Oral ivermectin 200 µg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivermectin 400 µg/kg</intervention_name>
    <description>Oral ivermectin 400 µg/kg three times (D0, D7 and D14) + topical treatment (permethrin 5% cream) on skin, hair and genital organs (D0 and D7) + emollient cream (Dexeryl® or other)daily on skin (D0 to D28)</description>
    <arm_group_label>Oral ivermectin 400 µg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Patients ≥ 18 years old, diagnosed with severe forms of scabies&#xD;
&#xD;
          1. clinical criteria : cutaneous lesions of scabies&#xD;
&#xD;
               -  crusted scabies: at least two sites of hyperkeratosis will define crusted scabies&#xD;
                  and/or&#xD;
&#xD;
               -  profuse scabies : spreading lesions with erythematous scaly eruption of the neck,&#xD;
                  face or trunk without hyperkeratosis&#xD;
&#xD;
          2. paraclinical criteria:&#xD;
&#xD;
               -  Positive parasitological test&#xD;
&#xD;
               -  and/or dermoscopic exam with signs of scabies&#xD;
&#xD;
        Effective contraception for women in age of pregnancy Written consent from patient or&#xD;
        his/her legal representant, trustworthy person or family member Affiliated to a social&#xD;
        security scheme&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant and/or breastfeeding women&#xD;
&#xD;
          -  Intolerance to ivermectin or topical treatment (permethrin 5% cream) or emollient&#xD;
             cream&#xD;
&#xD;
          -  Use of anti parasitic drug (ivermectin or albendazole) within the past 7 days&#xD;
&#xD;
          -  Abnormal liver test results: ALT and/or AST &gt;3N within the past 7 days (within 6&#xD;
             months if no hepatic history)&#xD;
&#xD;
          -  Participation in other biomedical drug research&#xD;
&#xD;
          -  Patient deprived of freedom&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giao DO-PHAM, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assistance Publique - Hôpitaux de Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Giao DO-PHAM, MD</last_name>
    <phone>(0)1 49 81 45 09</phone>
    <phone_ext>+33</phone_ext>
    <email>pham.do@chicreteil.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Henri Mondor Hospital</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laetitia Gregoire, M.Sc</last_name>
      <phone>(0) 1 49 81 41 64</phone>
      <phone_ext>+33</phone_ext>
      <email>laetitia.gregoire@aphp.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov/pubmed/24069468</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://www.cdc.gov/parasites/scabies/health_professionals/meds.html</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>June 30, 2016</study_first_submitted>
  <study_first_submitted_qc>July 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 22, 2016</study_first_posted>
  <last_update_submitted>November 19, 2020</last_update_submitted>
  <last_update_submitted_qc>November 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gale</keyword>
  <keyword>Severe forms of scabies</keyword>
  <keyword>Oral parasitic drug</keyword>
  <keyword>Ivermectin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Scabies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivermectin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

